Core Points - The sudden announcement of the death of Yin Zhenglong, the controlling shareholder and chairman of Shanhe Pharmaceutical Excipients, occurred on August 26, 2025, at the age of 60 [1][5][7] - Yin Zhenglong held 63,057,454 shares, accounting for 26.90% of the company's total shares, making him the controlling shareholder [7] - The company stated that Yin Zhenglong's death would not affect the normal operation of the board of directors, and the management team would continue to perform their duties [9] Company Background - Shanhe Pharmaceutical Excipients was founded in April 2001 and specializes in the production, research, and sales of new pharmaceutical excipients, currently holding a leading position in the domestic market [11] - The company was successfully listed on the Shenzhen Stock Exchange in May 2015, with a current market value of approximately 3.28 billion yuan [11] - Under Yin Zhenglong's leadership, the company grew from a small local pharmaceutical factory to a publicly listed company [10] Financial Performance - For the first half of 2025, Shanhe Pharmaceutical Excipients reported a revenue of 471 million yuan, a year-on-year increase of 4.65%, while the net profit attributable to shareholders decreased by 2.61% to approximately 93 million yuan [12][13] - The company reported a significant increase in cash flow from operating activities, which rose by 108.53% compared to the previous year [13] - The basic earnings per share decreased by 2.44% to 0.40 yuan, while diluted earnings per share fell by 5.00% to 0.38 yuan [13]

Core Viewpoint - The passing of Yin Zhenglong, the founder and chairman of Shanhe Pharmaceutical Auxiliary, marks a significant event for the company, which he led for over 20 years, establishing it as a key player in the pharmaceutical excipients industry [4][5][6]. Company Overview - Shanhe Pharmaceutical Auxiliary announced the death of its controlling shareholder and chairman, Yin Zhenglong, on August 26, 2025, at the age of 60 [1]. - The company has updated its official website to a black-and-white page as a sign of mourning [2]. - Yin Zhenglong chaired the sixth board meeting on the morning of August 26, where two key proposals were approved, including the half-year report for 2025 [4]. Leadership and Vision - As the founder, Yin Zhenglong played a crucial role in the company's growth from a local pharmaceutical factory to a publicly listed entity on the Shenzhen Stock Exchange [5]. - He emphasized the importance of "technical marketing" and "pre-marketing," advocating for sales personnel to possess technical knowledge to provide solutions to clients [4]. - Yin aimed to replace imported pharmaceutical excipients with domestic products, which was a key development goal for the company [4]. Shareholding and Management Transition - Yin Zhenglong held 26.90% of the company's shares, making him the controlling shareholder [6]. - The company stated that the inheritance of his shares will be handled according to legal regulations, and the board's operations remain unaffected [6]. - Song Daocai, a board member and general manager, has been appointed as the interim chairman and legal representative until a new chairman is elected [6].

Core Viewpoint - The passing of Yin Zhenglong, the controlling shareholder and chairman of Shanhe Pharmaceutical Auxiliary, marks a significant loss for the company and the industry, as he dedicated his life to the development of China's pharmaceutical sector and the company's growth [1][3]. Company Overview - Shanhe Pharmaceutical Auxiliary focuses on the research, production, and sales of pharmaceutical excipients, including fillers, adhesives, disintegrants, lubricants, and coating materials for oral solid dosage forms [4]. - As of August 26, the company's stock price was 14.34 yuan per share, with a total market capitalization of 3.4 billion yuan [4]. - The number of shareholders as of June 30, 2025, was 17,500 [4]. Leadership Transition - Following Yin Zhenglong's death, the company confirmed that the board of directors would remain operational, and the management team would continue its duties without disruption [4]. - The position of chairman is currently vacant, and the company will expedite the election of a new chairman in accordance with relevant laws and regulations [4]. - Until a new chairman is elected, the current director and general manager, Song Daocai, will temporarily assume the responsibilities of chairman and legal representative [4]. Contributions and Legacy - Yin Zhenglong was instrumental in transforming Shanhe Pharmaceutical Auxiliary from a local pharmaceutical factory into a publicly listed company on the Shenzhen Stock Exchange, contributing significantly to the domestic pharmaceutical excipient industry [3]. - His leadership and dedication earned him deep respect and affection from employees, and the company expressed heartfelt condolences to his family [3].

Group 1 - The core viewpoint of the article is the announcement of the passing of Yin Zhenglong, the controlling shareholder, actual controller, and chairman of the company, who died on August 26, 2025, at the age of 60 [1] - Yin Zhenglong held approximately 63.06 million shares, accounting for 26.9% of the company's total shares [3] - The company will handle the relevant procedures for the shares held by Yin Zhenglong according to applicable laws and regulations, and will fulfill its information disclosure obligations in a timely manner based on the progress of subsequent matters [3] Group 2 - The board of directors has elected Song Daocai, the company's director and general manager, to temporarily assume the duties of chairman and legal representative until a new chairman is elected by the board [3]

Core Viewpoint - The announcement reveals the passing of Mr. Yin Zhenglong, the controlling shareholder, actual controller, and chairman of Shanhe Pharmaceutical Auxiliary (300452.SZ) [1] Company Summary - Shanhe Pharmaceutical Auxiliary's controlling shareholder and chairman, Mr. Yin Zhenglong, has passed away [1]

Core Points - The controlling shareholder, actual controller, and chairman of Shanhe Pharmaceutical Auxiliary, Mr. Yin Zhenglong, has passed away [1] Company Summary - Shanhe Pharmaceutical Auxiliary (300452.SZ) has announced the death of its chairman, which may impact the company's leadership and strategic direction [1]

Core Viewpoint - The announcement details the passing of Yin Zhenglong, the controlling shareholder and chairman of Shanhe Pharmaceutical Auxiliary, which may impact the company's governance and future direction [1] Company Information - Yin Zhenglong passed away on August 26, 2025, at the age of 60 [1] - He held approximately 63.06 million shares, representing 26.9% of the company's total shares [1] - The company will handle the transfer of shares according to relevant laws and regulations [1] Management Transition - Following the passing of Yin Zhenglong, Song Daocai, a board member and general manager, has been appointed to temporarily assume the roles of chairman and legal representative [1] - This interim arrangement will remain until a new chairman is elected by the board [1]

Core Points - The company announced the passing of its founder and chairman, Mr. Yin Zhenglong, on August 26, 2025, at the age of 60 [1][2] - Mr. Yin was instrumental in the development of the Chinese pharmaceutical industry, focusing on domestic pharmaceutical excipients and achieving a transition from following to competing internationally [2] - The company will ensure that the board of directors remains functional and will not be affected by Mr. Yin's passing, with interim leadership provided by Mr. Song Daocai [3] Company Overview - Mr. Yin Zhenglong held 63,057,454 shares in the company, representing a significant portion of the total shares [2] - The company has a structured plan to elect a new chairman in accordance with legal regulations and its articles of association [3] - Mr. Song Daocai, currently the general manager, will temporarily assume the role of chairman until a new chairman is elected [3][5] Leadership Background - Mr. Song Daocai, aged 56, has extensive experience within the company, having held various positions since 2008, including production director and general manager [5] - He has a background in economic management and is a licensed pharmacist and engineer [5]

安徽山河药用辅料股份有限公司 证券代码:300452 证券简称:山河药辅 公告编号：2025-049 债券代码:123199 债券简称:山河转债 公司全体董事、高级管理人员和全体员工，对尹正龙先生为公 司付出的无数心血和做出的巨大贡献表示最衷心感谢，对尹正龙先生 的逝世致以沉痛哀悼和怀念，并向尹正龙先生的家人致以深切慰问。 尹正龙先生持有公司股份 63,057,454 股，占公司股份总额的 26.90%，为公司控股股东、实际控制人。尹正龙先生所持的公司股 份将按相关法律法规办理相关手续，公司将根据后续事项进展情况及 时履行信息披露义务。 尹正龙先生的逝世不会导致公司董事会成员人数低于法定人数， 不会影响公司董事会的正常运作。公司经营管理团队正常履职，各项 经营业务活动不会受到影响。公司董事长职位出现空缺，根据有关法 律法规和《公司章程》的规定，公司将尽快完成董事补选、选举董事 长等工作。经全体董事推举，现由公司董事、总经理宋道才先生（简 历详见附件）暂行行使公司董事长和法定代表人职责，直至公司董事 会选举出新的董事长之日止。 关于公司控股股东、实际控制人、董事长逝世的公告 本公司及董事会全体成员保证本公告内容 ...

Core Points - The company held its seventh meeting of the sixth board of directors on August 26, 2025, with all eight directors present, confirming compliance with relevant laws and regulations [1][2]. - The board approved the 2025 semi-annual report, affirming that the report accurately reflects the company's actual situation without any false statements or omissions [1][2]. - The board also approved a special report on the management and use of raised funds for the first half of 2025, confirming compliance with regulatory requirements [2]. Summary by Sections - **Meeting Details** - The meeting was attended by all eight directors, and the notice was sent out on August 17, 2025 [1]. - The meeting was chaired by Mr. Yin Zhenglong [1]. - **Approval of Semi-Annual Report** - The board reviewed and approved the 2025 semi-annual report, ensuring its authenticity and completeness [1][2]. - Voting results showed unanimous support with 8 votes in favor [2]. - **Approval of Fund Management Report** - The board approved a special report on the management and use of raised funds, confirming adherence to relevant regulations [2]. - This report was also reviewed and approved by the audit committee prior to the board meeting [2].